Targeting lipoprotein (a): an evolving therapeutic landscape

Current Atherosclerosis Reports
Lillian C ManDanielle Duffy

Abstract

Robust epidemiologic and genetic studies have solidified the role of lipoprotein (a) [Lp(a)] as an independent and causal risk factor for cardiovascular disease. The increased cardiovascular risk of Lp(a) is mediated through both proatherogenic and prothrombotic/antifibrinolytic mechanisms. Several societies recommend Lp(a) screening for patients with high cardiovascular risk, although no consensus exists on the management of patients with elevated Lp(a). However, numerous pharmacologic approaches are being evaluated that have the potential to reduce Lp(a) and will be the focus of this review. The majority of these interventions have been developed for other lipid-lowering indications, but also lower Lp(a). There are also novel therapies in development that specifically target Lp(a). The efficacy of these therapies varies, and their role in the evolving lipoprotein therapeutic landscape has yet to be determined. Nevertheless, targeted Lp(a) reduction is certainly intriguing and will likely continue to be an active area of investigation in the future.

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Nov 17, 1989·Science·G Utermann
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Dec 13, 1995·JAMA : the Journal of the American Medical Association·V M MaherJ J Albers
May 23, 1994·Archives of Internal Medicine·F M SacksB W Walsh
Jan 1, 1994·Chemistry and Physics of Lipids·M R SomaP Crosignani
Jan 23, 1999·The American Journal of Cardiology·D M CapuzziJ Brody
Jun 8, 2002·Atherosclerosis·Gérald LucUNKNOWN PRIME Study Group
Jul 2, 2002·JAMA : the Journal of the American Medical Association·Deborah GradyUNKNOWN HERS Research Group
Jul 17, 2003·European Journal of Clinical Investigation·A TavridouM F Laker
Jul 17, 2003·Current Opinion in Lipidology·Santica M Marcovina, Marlys L Koschinsky
Aug 9, 2003·The New England Journal of Medicine·JoAnn E MansonUNKNOWN Women's Health Initiative Investigators
Jul 8, 2005·The New England Journal of Medicine·Sotirios TsimikasPeter B Berger
May 6, 2006·Stroke; a Journal of Cerebral Circulation·Tetsuya OhiraAaron R Folsom
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Mar 26, 2008·Archives of Internal Medicine·Anna BennetVilmundur Gudnason
Mar 29, 2008·Atherosclerosis·G R Thompson, UNKNOWN HEART-UK LDL Apheresis Working Group
May 29, 2008·Nature Clinical Practice. Cardiovascular Medicine·Frederick F SamahaDaniel J Rader
Jul 3, 2008·Journal of Lipid Research·Claes BergmarkSotirios Tsimikas
Jul 5, 2008·Journal of the American College of Cardiology·Jacqueline Suk DanikPaul M Ridker
Jul 9, 2008·Current Opinion in Lipidology·Sotirios Tsimikas, Joseph L Witztum
Feb 24, 2009·Nature Clinical Practice. Cardiovascular Medicine·Beate R JaegerUNKNOWN Group of Clinical Investigators
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 11, 2009·Atherosclerosis·Gilbert R ThompsonS Watkins
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Dec 25, 2009·The New England Journal of Medicine·Robert ClarkeUNKNOWN PROCARDIS Consortium
Dec 25, 2009·The New England Journal of Medicine·Sekar Kathiresan
Mar 12, 2010·The New England Journal of Medicine·Paul W LadensonBo Angelin
May 8, 2010·Journal of the American College of Cardiology·Sebhat ErqouJohn Danesh
Oct 12, 2010·Current Opinion in Lipidology·Bo Angelin, Mats Rudling
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Apr 9, 2011·Journal of the American College of Cardiology·Esther MerkiSotirios Tsimikas
Jun 11, 2011·Journal of Lipids·Dipanjan BanerjeeLatha Palaniappan

❮ Previous
Next ❯

Citations

Dec 9, 2016·Expert Opinion on Emerging Drugs·Marie-Jeanne Bertrand, Jean-Claude Tardif
Feb 23, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Pankaj AroraMary Cushman
May 17, 2017·Current Treatment Options in Cardiovascular Medicine·Erik Kelly, Linda Hemphill
Feb 5, 2021·Chonnam Medical Journal·Taili LiuSang-Rok Lee
Apr 28, 2020·The American Journal of Cardiology·Nishant P ShahManesh R Patel

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Current Opinion in Lipidology
Brian Kolski, Sotirios Tsimikas
Current Cardiology Reports
Michael Boffa, Marlys Koschinsky
Current Opinion in Lipidology
Sven BosJeanine E Roeters van Lennep
Endocrinology and Metabolism Clinics of North America
Marlys Koschinsky, Michael Boffa
© 2022 Meta ULC. All rights reserved